Clinical Trial

Study of Recombinant Adenovirus AdVince in Patients With Neuroendocrine Tumors; Safety and Efficacy

Study acronym: RADNET
Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 3, 2024 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
An open-labelled, uncontrolled, single-center Phase I/IIa clinical study to evaluate the safety of repeated infusions of AdVince into the hepatic artery in patients with metastatic neuroendocrine tumors (NETs), and if possible determination of maximum tolerated dose.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2016-04-19; most recent amendment 2024-11-29.
Status change: Recruiting → Active, Not Recruiting 2024-11-29
Trial Details
NCT Number NCT02749331
Lead Sponsor Uppsala University
Conditions Neuroendocrine Tumors
Enrollment 35 participants
Start Date 2016-03
Primary Completion 2025-08 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-03